ICU MEDICAL INC/DE

Overview

ICU Medical, Inc. is a medical-device company focused on products used in infusion therapy, vascular access, and vital care. Its portfolio includes infusion pumps and safety software, IV sets and needle-free connectors, catheters, pharmacy-compounding systems, and respiratory, anesthesia, and patient-monitoring products.[1][2]

The company serves clinical customers worldwide. ICU Medical describes its mission as empowering clinicians to drive measurable improvements in patient care, with a purpose of supporting a healthcare experience free from preventable harm.[2][3]

For fiscal 2025, ended December 31, 2025, ICU Medical reported revenue of $2.231 billion.[4] [1]+4

Products & services

ICU Medical’s **Consumables** include infusion and vascular-access products such as Clave needlefree connectors and administration sets, the Neutron catheter-patency device, Tego dialysis/apheresis connector, and ClearGuard, SwabCap and SwabTip disinfection caps. Its oncology products include ChemoLock and ChemoClave closed-system transfer devices for hazardous-drug preparation and administration. Other named products include Jelco peripheral IV catheters and sharps-safety devices, Safe-T Wing blood-collection devices, Port-A-Cath implantable ports, PowerWand midline catheters, and Cleo subcutaneous infusion catheters and sets.[5]+14

Its **Infusion Systems** portfolio includes large-volume, ambulatory and syringe pumps, dedicated IV sets, medication-safety software and related clinical and technical services. Plum Duo and Plum Solo are single- and dual-channel precision pumps; the dual-channel configuration can deliver up to four compatible medications, with stated delivery accuracy of ±3%. Plum 360 uses a cassette system, and PlumSet administration sets include an air trap and direct secondary-line connection. Software offerings include LifeShield, ICU Medical MedNet and PharmGuard; services include customized configuration, implementation and data analytics.[20]+8

**Vital Care** products span hemodynamic monitoring, anesthesia and respiratory care, temperature management, regional anesthesia and pain management. Named monitoring products include Cogent, CardioFlo, TDQ and OptiQ systems and catheters, TriOx venous-oximetry catheters, Transpac blood-pressure transducers and the SafeSet blood-sampling system. The line also includes Portex acapella bronchial-hygiene products and Level 1 fluid, blood and irrigation warming and patient-warming systems. ICU Medical sells and distributes IV Solutions—including IV therapy and diluent solutions such as saline, dextrose and electrolyte solutions, plus irrigation solutions—under a commercial agreement following transfer of the product line to a joint venture in 2025.[29]+16

For fiscal 2025, Consumables accounted for 50% of revenue ($1.109 billion), Infusion Systems 31% ($684.2 million), and Vital Care 19% ($437.9 million).[46] [5]+41

Geographic presence

ICU Medical’s manufacturing footprint spans the United States, Mexico, Costa Rica, the Czech Republic and Italy. Its filings identify facilities in Ensenada, Monterrey and Tijuana, Mexico; La Aurora, Costa Rica; Hranice, Czech Republic; Latina, Italy; and multiple U.S. locations. Salt Lake City manufactures Clave products and supplies components to facilities in Ensenada and Costa Rica; Austin, Texas, manufactures IV Solutions products for the Otsuka ICU Medical joint venture. The company says a meaningful portion of its global revenue comes from products manufactured in Costa Rica and Mexico and imported into the United States.[47]+2

The company also lists corporate, research and development, distribution, warehouse and device-service locations across North America, Europe, Asia and Australia, including sites in the Netherlands, the United Kingdom, Germany, India and Australia. Tijuana is described on the company’s careers site as its largest manufacturing facility, with approximately 2,500 employees.[50][51]

The FY2025 filing does not provide revenue percentages by country or region; its geographic asset disclosures should not be interpreted as revenue mix.[52] [47]+7

Business segments

ICU Medical reports one operating and reportable segment, covering its medical-products business; its product-line categories are not separate reportable segments. The company states that it does not allocate all costs and operating expenses to product lines, with relevant expenses reported to its chief operating decision maker on a consolidated basis.[53][54] [53][54]

Company history

Founded in 1984, ICU Medical traces its origins to clinician and founder George “Doc” Lopez and the development of needlefree connector technology. The company completed its initial public offering in 1992.[55][56]

In 2012, ICU Medical introduced its NanoClave needlefree connector, and in 2014 Vivek Jain became chairman and CEO.[57][58] The company expanded into infusion systems by completing its acquisition of Hospira Infusion Systems in 2017, followed by its acquisition of Smiths Medical in 2022, adding syringe and ambulatory infusion devices, vascular access, and vital-care products.[59][60] In 2025, ICU Medical completed a transaction in which Otsuka acquired a 60% interest in ICU Medical’s IV Solutions business, with ICU Medical retaining 40%.[61][62] [55]+7

Sources

• ICU MEDICAL INC/DE — Full financial report (2025 Y)
  9 citations

  [1][2][46][47][48][49][50][53][61]
• www.icumed.com[3]
• ICU MEDICAL INC/DE — Press release (2025 Y)[4]
• ICU MEDICAL INC/DE — Full financial report (2026 Q 2)
  42 citations

  [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][54]
• www.icumed.com[51]
• www.sec.gov[52]
• ICU MEDICAL INC/DE — Full financial report (2024 Y)[55]
• ir.icumed.com[56]
• ir.icumed.com[57]
• ir.icumed.com[58]
• ir.icumed.com[59]
• ir.icumed.com[60]
• ir.icumed.com[62]